Iwalokun B A
Department of Biochemistry, Lagos State University, Ojo, P.M.B 1087, Apapa-Lagos, Nigeria. bamwal@yahoo
Afr Health Sci. 2008 Mar;8(1):25-35.
The emergence and spread of Plasmodium falciparum with resistance to chloroquine (CQ), the safest and cheapest antimalarial drug coupled with the increasing cost of alternative drugs especially in developing countries have necessitated the need to optimize antimalarial actions of plant extracts and restore chloroquine efficacy.
The present study determines the ability of Vernonia amygdalina leaf extract to enhance the prophylactic and therapeutic efficacy of chloroquine against Plasmodium berghei malaria in mice.
Chloroquine sensitive (P. berghei(S)) and resistant (P.berghei(R)) ANKA clones of Plasmodium berghei maintained by serial passage in mice were used to develop respective experimental rodent malaria models based on intraperitoneal injection of 10(6) parasitize erythrocyte suspension in PBS (pH 7.2) and subsequent development of parasitaemia. These models were then used to investigate the prophylactic enhancement of chloroquine (CQ) at 5 mg/kg via combination with selected doses (31.25, 62.5, 125mg/kbw) of Vernonia amygdalina leaf extracts using a 4-day suppression test. Effect of these combinations on the therapeutic efficacy of CQ at 30mg/kg over 3 days were evaluated. Treatment outcomes including parasite clearance (PCT) and rescrudescent time (RT) were compared with CQ-chlorpheniramine combination. The acute toxicity of the extract-CQ combinations was also determined enzymatically.
Prophylatically, chloroquine (5mg/kg) in combination with vernonia extracts achieved a dose-dependent (57.2-72.7%) suppression of parasitaemia due to CQ sensitive and resistant P berghei strains in the experimental animals. Therapeutically, chloroquine (30mg/kg for 3 days) combined with vernonia to dose-dependently shorten the parasite clearance times (2.6-4.4 vs. 4.8 days; P < 0.05 for CQ-V62.5/125 combination), prolong the recrudescent times (8.9-18.9 vs. 7.2 days; P < 0.05) and improve day 14 cure rate (66.7-100 vs. 58.3%) in the treated P. berghei(S) infected mice compared to CQ monotherapy. Whereas CQ monotherapy failed, resolution of parasitaemia due to the CQ resistant parasite with day 14 cure rates of 25 - 100% were also observed with these combinations. In therapeutic terms, the potencies of CQ-V125 combination were comparable to those of CQ-chlorpheniramine (0.25mg/kg, 12hourly, 7 days) in the infected animals. Toxicity testing indicates that these combinations elicited mild to moderate increases in the liver enzymes measured when administered orally to mice for 7 days.
This study indicates that Vernonia amygdalina leaf extract dose-dependently restore the efficacy of CQ against CQ resistance P. berghei malaria in mice.
恶性疟原虫对氯喹(CQ)产生耐药性,氯喹是最安全且最便宜的抗疟药物,而在发展中国家,替代药物成本不断增加,因此需要优化植物提取物的抗疟作用并恢复氯喹的疗效。
本研究旨在确定扁桃斑鸠菊叶提取物增强氯喹对小鼠伯氏疟原虫疟疾预防和治疗效果的能力。
通过在小鼠体内连续传代维持的氯喹敏感(伯氏疟原虫(S))和耐药(伯氏疟原虫(R))ANKA克隆,基于腹腔注射10⁶个寄生红细胞悬液于PBS(pH 7.2)中并随后出现寄生虫血症,建立各自的实验性啮齿动物疟疾模型。然后使用这些模型,通过4天抑制试验,研究氯喹(5mg/kg)与选定剂量(31.25、62.5、125mg/kbw)的扁桃斑鸠菊叶提取物联合使用时对其预防效果的增强作用。评估这些联合用药对30mg/kg氯喹在3天内治疗效果的影响。将包括寄生虫清除(PCT)和复发时间(RT)在内的治疗结果与氯喹 - 氯苯那敏联合用药进行比较。还通过酶法测定提取物 - 氯喹联合用药的急性毒性。
在预防方面,氯喹(5mg/kg)与扁桃斑鸠菊提取物联合使用,对实验动物中氯喹敏感和耐药的伯氏疟原虫菌株引起的寄生虫血症实现了剂量依赖性(57.2 - 72.7%)抑制。在治疗方面,氯喹(30mg/kg,连续3天)与扁桃斑鸠菊联合用药可剂量依赖性地缩短寄生虫清除时间(2.6 - 4.4天对4.8天;氯喹 - V62.5/125联合用药P < 0.05),延长复发时间(8.9 - 18.9天对7.2天;P < 0.05),并提高治疗的伯氏疟原虫(S)感染小鼠第14天的治愈率(66.7 - 100%对58.3%),与氯喹单药治疗相比。虽然氯喹单药治疗失败,但这些联合用药也观察到对氯喹耐药寄生虫引起的寄生虫血症的消退,第14天治愈率为25 - 100%。在治疗效果方面,氯喹 - V125联合用药的效力与感染动物中氯喹 -
氯苯那敏(0.25mg/kg,每12小时一次,共7天)相当。毒性测试表明,这些联合用药在对小鼠口服给药7天时,引起所测肝酶轻度至中度升高。
本研究表明,扁桃斑鸠菊叶提取物剂量依赖性地恢复氯喹对小鼠氯喹耐药伯氏疟原虫疟疾的疗效。